France Nephrology and Urology Devices Market Outlook to 2025 - Renal Dialysis Equipment

Table of Contents

• 1.1 List of Tables 4
• 1.2 List of Figures 4

2 Introduction 5

• 2.1 What Is This Report About? 5
• 2.2 Nephrology and Urology Devices Market Segmentation 5
• 2.3 Definitions of Markets Covered in the Report 6

3 Nephrology and Urology Devices Market, France 8

• 3.1 Nephrology and Urology Devices Market, France, Revenue ($m), 2015-2025 8
• 3.2 Nephrology and Urology Devices Market, France, Revenue ($m), 2015-2025 10
• 3.3 Nephrology and Urology Devices Market, France, Volume (Units), 2015-2025 12
• 3.4 Nephrology and Urology Devices Market, France, Volume (Units), 2015-2025 14
• 3.5 Nephrology and Urology Devices Market, France, Company Share by Revenue ($m), 2019 16

4 Renal Dialysis Equipment Market, France 18

• 4.1 Renal Dialysis Equipment Market, France, Revenue Mix ($m), 2019 18
• 4.2 Renal Dialysis Equipment Market, France, Segment Contribution (%), 2019 19
• 4.3 Renal Dialysis Equipment Market, France, Revenue ($m), 2015-2025 20
  • 4.3.1 Dialysis Accessories Market, France, Revenue ($m), by Segment, 2015-2025 22
  • 4.3.2 Dialysis Machines Market, France, Revenue ($m), by Segment, 2015-2025 25
  • 4.3.3 Vascular Access Devices for Hemodialysis Market, France, Revenue ($m), by Segment, 2015-2025 27
• 4.4 Renal Dialysis Equipment Market, France, Volume (Units), 2015-2025 30
  • 4.4.1 Dialysis Accessories Market, France, Volume (Units) by Segment, 2015-2025 32
  • 4.4.2 Dialysis Machines Market, France, Volume (Units) by Segment, 2015-2025 35
  • 4.4.3 Vascular Access Devices for Hemodialysis Market, France, Volume (Units) by Segment, 2015-2025 37
• 4.5 Renal Dialysis Equipment Market, France, Average Price ($), 2015-2025 40
• 4.6 Renal Dialysis Equipment Market, France, Distribution Share by Revenue ($m), 2019 42
• 4.7 Renal Dialysis Equipment Market, France, Company Share by Revenue ($m), 2019 43

5 Overview of Key Companies in France, Nephrology and Urology Devices Market 45

• 5.1 Fresenius Medical Care AG & Co KGaA 45
  • 5.1.1 Company Overview 45
• 5.2 Nipro Corp 45
  • 5.2.1 Company Overview 45
• 5.3 Baxter International Inc 45
  • 5.3.1 Company Overview 45
• 5.4 B. Braun Melsungen AG 46
  • 5.4.1 Company Overview 46
• 5.5 Asahi Kasei Corp 46
  • 5.5.1 Company Overview 46
• 5.6 Toray Medical Co Ltd 46
  • 5.6.1 Company Overview 46
• 5.7 CR Bard Inc 47
  • 5.7.1 Company Overview 47
• 5.8 Medtronic plc 47
  • 5.8.1 Company Overview 47

6 Nephrology and Urology Devices Market Pipeline Products 48

7 Financial Deals Landscape 51

• 7.1 Debt Offerings 51
  • 7.1.1 Sanofi Prices Public Offering of 1.000% Notes Due 2025 for USD804.8 Million 51
  • 7.1.2 Sanofi Prices Public Offering of 1.500% Notes Due 2030 for USD804.8 Million 52
• 7.2 Partnerships 53
  • 7.2.1 Osprey Medical to Enter into Distribution Agreement with GE Healthcare 53

8 Recent Developments 54

• 8.1 Corporate Communications 54
  • 8.1.1 Mar 04, 2020: Sanofi's Board of Directors proposes the appointment of Rachel Duan and Lise Kingo as independent directors 54
  • 8.1.2 Feb 25, 2020: Sanofi announces resignation of Director 55
  • 8.1.3 Jan 14, 2020: Vygon appoints new CEO for Vygon USA 55
  • 8.1.4 Aug 20, 2019: Forendo Pharma commences phase 1b proof of mechanism study with its lead endometriosis program, HSD17B1 inhibitor FOR-6219 56
  • 8.1.5 Jul 29, 2019: Sanofi: Appointment of additional director and whole time director 56
  • 8.1.6 Jul 26, 2019: Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer 57
  • 8.1.7 Jun 07, 2019: Paul Hudson to succeed Olivier Brandicourt as chief executive officer 58
  • 8.1.8 Jun 05, 2019: Affluent Medical strengthens its executive team 58
• 8.2 Financial Announcements 60
  • 8.2.1 Feb 06, 2020: Sanofi delivers strong 2019 business EPS growth of 6.8% at CER 60
  • 8.2.2 Nov 13, 2019: EDAP reports 2019 third quarter and nine months results 69
  • 8.2.3 Oct 31, 2019: Sanofi Q3 well on track 70
  • 8.2.4 Aug 28, 2019: EDAP reports 2019 second quarter results 73
  • 8.2.5 Aug 19, 2019: Nascent Biotech has entered into an agreement to perform phase I clinical study for brain cancer 74
  • 8.2.6 Jul 29, 2019: Sanofi delivered solid growth in Q2 2019 75
  • 8.2.7 Jul 25, 2019: EDAP TMS pre-announces strong 98% groth in HIFU sales in the second quarter 2019 84
  • 8.2.8 May 15, 2019: EDAP announces 2019 First Quarter Results 84
• 8.3 Other Significant Developments 85
  • 8.3.1 Mar 05, 2020: ADDvise signs a new agreement with Laborie with a total order value of at least MSEK 50 85
  • 8.3.2 Apr 26, 2019: Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER 85
• 8.4 Strategy And Business Planning 92
  • 8.4.1 Oct 15, 2019: Sanofi opens digital manufacturing facility in the US 92
  • 8.4.2 May 21, 2019: Verily forms strategic alliances with Novartis, Otsuka, Pfizer and Sanofi to transform clinical research 92

9 Appendix 95

• 9.1 Research Methodology 96
  • 9.1.1 Coverage 96
  • 9.1.2 Secondary Research 96
  • 9.1.3 Primary Research 97
  • 9.1.4 Market Modeling and Forecasting 97
  • 9.1.5 Company Share Analysis 99
  • 9.1.6 Distribution Share Analysis 99
  • 9.1.7 Benchmarking 100
• 9.2 GlobalData Consulting 100
• 9.3 Contact Us 101